Cardiff drops its prostate can­cer pro­gram, send­ing shares in­to a tail­spin

Cardiff On­col­o­gy is join­ing the league of com­pa­nies that have de­cid­ed to scrap one of its pro­gram, lead­ing the com­pa­ny’s stock to take a nose dive on Tues­day.

The com­pa­ny an­nounced that it will no longer fund its clin­i­cal tri­als for prostate can­cer and in­stead will fo­cus its ef­forts on pan­cre­at­ic and metasta­t­ic col­orec­tal can­cer.

The com­pa­ny is test­ing its lead can­di­date, on­va­nsert­ib, a PLK1 in­hibitor, along with the stan­dard of care in a va­ri­ety of in­di­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER